Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Maaike Dotinga"'
Autor:
Maaike Dotinga, Dennis Vriens, Floris H. P. van Velden, Mette K. Stam, Jan W. T. Heemskerk, Petra Dibbets-Schneider, Martin Pool, Daphne D. D. Rietbergen, Lioe-Fee de Geus-Oei, Ellen Kapiteijn
Publikováno v:
Diagnostics, Vol 12, Iss 12, p 3154 (2022)
Background: Management of patients with radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) is a challenge as I-131 therapy is deemed ineffective while standard-of-care systemic therapy with tyrosine kinase inhibitor (TKI) lenvatinib is
Externí odkaz:
https://doaj.org/article/a3e65c56397e47b3a4b9c7a4a1606cf9
Autor:
Rodney J. Hicks, Ellen Kapiteijn, Dennis Vriens, Lioe-Fee de Geus-Oei, James Nagarajah, Floris H. P. van Velden, Maaike Dotinga, Linda Heijmen
Publikováno v:
Quarterly Journal of Nuclear Medicine and Molecular Imaging, 64, 250-264
Quarterly Journal of Nuclear Medicine and Molecular Imaging, 64(3), 250-264. EDIZIONI MINERVA MEDICA
Quarterly Journal of Nuclear Medicine and Molecular Imaging, 64, 3, pp. 250-264
Quarterly Journal of Nuclear Medicine and Molecular Imaging, 64(3), 250-264. EDIZIONI MINERVA MEDICA
Quarterly Journal of Nuclear Medicine and Molecular Imaging, 64, 3, pp. 250-264
Item does not contain fulltext Poor responses to iodine-131 (I-131) therapy can relate to either low iodine uptake and retention in thyroid cancer cells or to increased radioresistance. Both mechanisms are currently termed radioactive iodine (RAI)-re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8bc9e6441633575b6d5e256d73f9226
https://hdl.handle.net/2066/225889
https://hdl.handle.net/2066/225889